RxDoctor Payments Data

Carol Bretschneider, MD

Urogynecology and Reconstructive Pelvic Surgery · Chicago, ILNPI 1700146826

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (38.6%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 62.6% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2023 at $4,767 and has fallen 61.2% since, to $1,852 in 2025.

$13,545in general payments, 2019–2025

Across 82 payments — averaging $165.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$8K
  • Axonics, Inc.$2K
  • Medtronic$2K
  • AbbVie$248
  • Avation Medical, Inc.$169
  • Coloplast$80
  • plus $55 from 1 others
$6,975in research payments, 2019–2025

Across 3 payments — averaging $2325.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Axonics, Inc.$7K

What the payments were for

  • Consulting fees$5,22639%
  • Speaking & faculty fees$4,07330%
  • Travel & lodging$1,38110%
  • Food & beverage$2,86521%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific29$8,475
Axonics, Inc.20$2,327
Medtronic(2 entities)20$2,190
AbbVie9$248
Avation Medical, Inc.1$169
Coloplast1$80
Applied Medical Resources Corporation2$55

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,545 in reported general payments places this provider in the 80th percentile of 62 urogynecology and reconstructive pelvic surgery providers in Illinois.

See all urogynecology and reconstructive pelvic surgery providers in Illinois

Medicare billing

Part B allowed, 2024
$302,242
Medicare patients
463
Services billed
10,746

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron74$44,721
MyrbetriqMirabegron63$35,087
Estradiol199$11,775
Methenamine Hippurate21$999
YuvafemEstradiol13$936
Clobetasol Propionate12$887
Tolterodine Tartrate ErTolterodine Tartrate13$332
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst30$245

Paid to pharmacies, not to this prescriber.

Other urogynecology and reconstructive pelvic surgery in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →